Puma Biotechnology, INC

Puma Biotechnology reported Q1 2026 results with a slight revenue decrease but raised full-year revenue and net income guidance, driven by increased demand for NERLYNX and positive interim data for alisertib.

Puma Biotechnology announced its fourth quarter and full year 2025 financial results, showing increased product revenue but a decline in Q4 net income due to tax adjustments, alongside significant debt reduction.

Puma Biotechnology reported third quarter 2025 financial results, raising its full-year NERLYNX revenue and net income estimates driven by increased U.S. demand.

Puma Biotechnology reported a significant turnaround to net income in the second quarter of 2025, driven by increased sales of its flagship cancer drug, NERLYNX.

Puma Biotechnology, Inc. has adopted Fifth Amended and Restated Bylaws to update corporate governance provisions, primarily aligning them with recent changes in Delaware law and formalizing procedures for shareholder engagement and director nominations.

Puma Biotechnology, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all eight nominated directors were elected, KPMG LLP was ratified as the independent accounting firm, and executive compensation was approved on an advisory basis.

Puma Biotechnology reported a slight revenue decrease in Q1 2026, with product revenue at $42.0 million, while research and development expenses surged due to increased alisertib study activity.

Puma Biotechnology, Inc. amended its Note Purchase Agreement, extending a key equity issuance deadline while reporting a decrease in total revenue for the third quarter and first nine months of 2025.

Puma Biotechnology, Inc. reported a significant turnaround to net income and increased revenue for the second quarter and first half of 2025, driven by strong NERLYNX sales and reduced operating expenses, despite ongoing patent litigation challenges.

Puma Biotechnology, Inc. filed an amendment to its first-quarter 2025 report to disclose an inadvertently omitted Rule 10b5-1 trading arrangement for a board member and include updated certifications.

Puma Biotechnology announces a profitable first quarter in 2025, with net income driven by increased product revenue and strategic expense management.

Puma Biotechnology's Q3 2024 results show a significant increase in total revenue, primarily driven by a surge in royalty revenue and a modest increase in product sales.

Puma Biotechnology's 2025 Annual Report details increased NERLYNX product revenue, ongoing alisertib clinical trials, and significant legal challenges impacting international markets and patent validity.

Puma Biotechnology reports a profitable year in 2024 with $230.5 million in revenue, while actively managing patent litigation and advancing its drug pipeline.

Puma Biotechnology's 2023 annual report details financial performance, ongoing commercialization of NERLYNX, and development plans for alisertib.

Alan H. Auerbach, Director, President and CEO of Puma Biotechnology, Inc., reported a transaction involving the sale of common stock.

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, Inc., reported a transaction involving the sale of common stock.

Puma Biotechnology's Chief Financial Officer, Maximo F. Nougues, reported the sale of 9,386 shares of common stock on July 6, 2026, under a pre-arranged 10b5-1 trading plan.

Director Troy E. Wilson acquired 27,000 restricted stock units and sold 10,800 shares of Puma Biotechnology common stock.

Director Brian M. Stuglik acquired 27,000 restricted stock units and sold 8,100 shares of Puma Biotechnology common stock.

Director Adrian Senderowicz acquired 27,000 restricted stock units and subsequently sold 27,000 shares of Puma Biotechnology common stock.

Puma Biotechnology, Inc. has announced its 2026 annual meeting of stockholders, scheduled for June 11, 2026, to elect directors, ratify auditors, and vote on executive compensation and an extension of CEO Alan H. Auerbach's warrant.

Puma Biotechnology has filed a definitive proxy statement with the Securities and Exchange Commission.

Puma Biotechnology's proxy statement details the agenda for the 2025 annual meeting, including director elections, auditor ratification, and an advisory vote on executive compensation.

Puma Biotechnology has filed a definitive proxy statement with the SEC.

Puma Biotechnology is asking stockholders to approve an amendment to its 2011 Incentive Award Plan to increase the number of shares available for issuance and extend the period for granting incentive stock options.

The Vanguard Group reports zero beneficial ownership in Puma Biotechnology Inc. following an internal realignment.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Puma Biotechnology Inc. as of March 31, 2025.

Acorn Bioventures, L.P., Acorn Bioventures 2, L.P., their general partners, and manager Anders Hove have filed an amended Schedule 13G, disclosing their collective passive beneficial ownership of 8.0% of Puma Biotechnology, Inc.'s common stock as of December 31, 2024.

A recent SEC filing reveals that the Frazier Life Sciences investment group has reduced its beneficial ownership in Puma Biotechnology, Inc. to 0.0%, indicating a complete divestment of its previously held stake.

Camber Capital Management LP and Stephen DuBois have filed an amendment to their Schedule 13G, indicating they no longer hold any beneficial ownership in Puma Biotechnology, Inc. as of December 31, 2024.

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, updating their passive beneficial ownership in Puma Biotechnology, Inc. as of December 31, 2024.